Lumen Bioscience
Lumen Bioscience is a Seattle-based clinical-stage biotech that engineers spirulina algae to produce oral biologic drugs at 100–1000x lower cost than traditional biomanufacturing. It serves patients with C. difficile, obesity, IBD, kidney stones, gastroenteritis, respiratory viruses, and malaria across a seven-program pipeline.
- Company typePrivate
- Founded2017
- HeadquartersSeattle, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lumen Bioscience does
Lumen Bioscience is a privately held, clinical-stage biopharmaceutical company headquartered in Seattle that develops and manufactures oral biologic drug candidates using a proprietary spirulina-based biomanufacturing platform. Founded in 2017, the company was the first to successfully engineer Arthrospira platensis (edible blue-green algae) to express therapeutic proteins, a breakthrough that had eluded researchers for decades and is protected by 34 issued patents with 24 pending. The platform requires only water, salt, CO₂, and light for production, eliminates the need for sterility or complex downstream purification, and delivers therapeutic proteins at costs two to three orders of magnitude lower than traditional E. coli, CHO cell, or yeast biomanufacturing systems. Production is conducted at a fully integrated cGMP facility in Seattle with capacity of 15+ kg of GMP drug substance per week.
The company's pipeline includes seven candidates across infectious disease, metabolic disease, nephrology, gastroenterology, and global health. Lead program LMN-201, an oral biologic cocktail for C. difficile infection, is in Phase 2/3 (RePreve Trial) and demonstrated 100% initial clinical cure (21/21 patients) with 4.76% recurrence in its April 2025 sentinel cohort, materially outperforming historical standard-of-care and bezlotoxumab benchmarks; full Phase 3 results are expected in June 2026. LMN-801, an oral hormone protein for weight loss, is in Phase 2. Additional programs include an oral oxalate-degradation enzyme (Phase 2/3 ready), an IBD biologic (preclinical), an oral gastroenteritis antibody cocktail (Phase 1), an intranasal respiratory virus biologic (Phase 1), and an intranasal malaria vaccine (preclinical).
Lumen has raised over $185 million to date through a mix of equity and non-dilutive funding from the U.S. Department of Defense, NIH/NIAID, the Bill & Melinda Gates Foundation, CARB-X, MTEC, and venture capital investors. The company is pre-revenue, generates no commercial product sales, and is building commercial infrastructure for a U.S.-first launch followed by global rollout. Its go-to-market strategy blends eventual direct sales into hospital and retail pharmacy channels with potential out-licensing transactions, as indicated by CEO-disclosed inbound licensing interest from pharma companies for its C. difficile and weight loss candidates.
Lumen Bioscience firmographics
Firmographics- Name
- Lumen Bioscience
- Legal name
- Lumen Bioscience, Inc.
- Website
- https://lumen.bio
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Lumen Bioscience is a Seattle-based clinical-stage biotech that engineers spirulina algae to produce oral biologic drugs at 100–1000x lower cost than traditional biomanufacturing. It serves patients with C. difficile, obesity, IBD, kidney stones, gastroenteritis, respiratory viruses, and malaria across a seven-program pipeline.
- Ownership category
- akta.pro rank
Lumen Bioscience industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Lumen Bioscience is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Lumen Bioscience business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Biopharmaceutical Product Sales: The company is developing multiple biologic drug candidates across clinical pipeline. Once approved, products will be commercialized through pharmaceutical distribution channels. Lead program LMN-201 targets C. difficile infection with Phase 2/3 ongoing. Other programs include weight loss (LMN-801), IBD, oxalate degradation, gastroenteritis, viral respiratory infections, and malaria.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
Lumen Bioscience product offering
Product offeringCore offering
Lumen Bioscience discovers, develops, and manufactures biologic drug and vaccine candidates using a proprietary spirulina (edible blue-green algae) biomanufacturing platform. The company engineers Arthrospira platensis to express therapeutic proteins, enabling oral biologic delivery at costs two to three orders of magnitude lower than traditional biomanufacturing. Its clinical pipeline targets C. difficile infection, obesity, IBD, kidney stones, gastroenteritis, viral respiratory infections, and malaria.
Product overview
Lumen Bioscience is a drug development company with a proprietary biomanufacturing platform using engineered spirulina (edible blue-green algae) to produce therapeutic proteins. The platform enables oral delivery of biologics at significantly reduced costs. The company's core pipeline includes: LMN-201 (Phase 2/3) - oral biologic cocktail for C. difficile infection; LMN-801 (Phase 2) - oral hormone protein for weight loss; oxalate degradation product (Phase 2/3 ready) - enzyme supplement for kidney stone prevention; IBD product (preclinical) - oral biologic for Crohn's disease and ulcerative colitis; gastroenteritis antibody cocktail (Phase 1); viral respiratory infections intranasal biologic (Phase 1); and malaria intranasal vaccine (preclinical). All products are developed using the spirulina-based manufacturing platform.
Differentiator
Problem solved
Functional benefit
Products and services
- LMN-201
Quantifiable outcome
- 100% initial C. difficile clinical cure rate (21/21 patients) in Phase 2/3 RePreve Trial sentinel cohort
- +3 more outcomes
Companies that use Lumen Bioscience
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles3 records
Lumen Bioscience technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Lumen Bioscience partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- Fred Hutchinson Cancer Research CentercoreResearch collaboration with scientific advisors including Jim Roberts, Co-Founder who was Director in the Basic Sciences Division. Co-inventor of mammalian cell transformation technology.
- University of WashingtonmajorAcademic research partner with multiple collaborations. Located nearby in Seattle. Scientific advisors include experts from UW School of Medicine in gastroenterology, metabolism, and nephrology.
- Rockefeller UniversitymajorResearch collaborator in pipeline programs, particularly in the C. difficile program shown in pipeline with Rockefeller University logo.
- Novo NordiskmajorResearch collaboration as shown in pipeline partners section, potentially related to metabolic disease/weight loss programs.
- Institute for Protein Design (UW)majorCollaboration in protein engineering and design, leveraging advanced computational methods for therapeutic protein development.
- Tufts University (Cummings School of Veterinary Medicine)minorResearch collaborator in veterinary applications and potential animal health uses of the platform technology.
- Monash UniversityminorInternational academic research collaborator in biotechnology and biomedical research.
- University of VirginiaminorResearch collaboration including scientific advisor Jim Nataro, Professor and Chair of Pediatrics, involved in global health and infectious disease research.
- MassBiominorMassachusetts biotech industry association partnership supporting biotech ecosystem and collaboration.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Lumen Bioscience competitors and assessment
Company assessmentDirect peers
- Protalix BioTherapeutics: Protalix is a clinical-stage company that manufactures therapeutic proteins using a plant-cell-based (carrot/chemically-induced) expression system. It is the most direct peer to Lumen's plant-based biologic manufacturing approach, sharing the core thesis that non-mammalian hosts can dramatically reduce cost and complexity of biologic production.
- Seres Therapeutics: Seres is a microbiome therapeutics company whose VOWST was the first FDA-approved oral microbiome therapeutic for prevention of recurrent C. difficile infection. It is a direct competitor to Lumen's LMN-201 in the CDI recurrence setting and operates in the same clinical and commercial pathway.
- Vedanta Biosciences: Vedanta is developing defined bacterial consortia (VE303) for recurrent C. difficile infection, in direct competition with Lumen's LMN-201. Both companies are clinical-stage and target CDI recurrence, an indication with $5-8B in U.S. annual healthcare costs.
Emerging players
- Novavax: Novavax uses a protein-based nanoparticle platform to produce recombinant vaccines, sharing Lumen's strategy of producing complex protein therapeutics in non-mammalian systems for infectious disease indications. Both companies emphasize cost-effective, scalable production for global vaccine markets.
- Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology platform company that engineers microorganisms (including algae) for industrial bioproduction. While broader in scope, it shares Lumen's strategy of programming non-mammalian organisms to produce high-value biological products.
- Absci: Absci is an AI-driven generative biology company focused on designing and producing novel therapeutic antibodies and biologic drugs. It shares Lumen's emphasis on computational protein engineering and offers an alternative platform for low-cost biologic development.
- InVitria: InVitria develops recombinant protein production technologies and cell culture media components for biomanufacturing. It overlaps with Lumen's bioprocess technology and consumables theme, though focused on traditional mammalian cell culture vs. Lumen's spirulina approach.
Broad incumbents
- Amgen: Amgen is a global biopharma leader in biologic drug manufacturing and antibody therapeutics, with a broad infectious disease and inflammation portfolio. It is a broad incumbent that competes with Lumen in commercial-stage biologics and has partnered with Lumen scientific advisors.
- Genentech (Roche): Genentech pioneered recombinant antibody manufacturing and remains the global leader in monoclonal antibody therapeutics, including treatments for CDI-associated inflammation and IBD. It is a broad incumbent that competes in Lumen's target therapeutic areas using traditional CHO-based manufacturing.
- BioMarin Pharmaceutical: BioMarin is a clinical and commercial-stage biologics manufacturer focused on rare and serious diseases, using mammalian and microbial expression systems. It is a broad incumbent in specialty biologics and represents the kind of large biopharma partner that could license Lumen's platform or individual programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Lumen Bioscience social profiles
Digital presenceLumen Bioscience financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lumen Bioscience leadership team
Management profileNumber of profiles
Profiles27 records
Lumen Bioscience funding detail
Funding detailFunding overview
Funding rounds9 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lumen Bioscience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lumen Bioscience
What does Lumen Bioscience do?
Lumen Bioscience discovers, develops, and manufactures biologic drug and vaccine candidates using a proprietary spirulina (edible blue-green algae) biomanufacturing platform. The company engineers Arthrospira platensis to express therapeutic proteins, enabling oral biologic delivery at costs two to three orders of magnitude lower than traditional biomanufacturing. Its clinical pipeline targets C. difficile infection, obesity, IBD, kidney stones, gastroenteritis, viral respiratory infections, and malaria.
Is Lumen Bioscience a public or private company?
Lumen Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lumen Bioscience founded?
Lumen Bioscience was founded in 2017. It employs 101 to 250 people.
Where is Lumen Bioscience based?
Lumen Bioscience is headquartered in Seattle, United States, in the North America region.
How does Lumen Bioscience make money?
One revenue line is on record: biopharmaceutical Product Sales.
Who are Lumen Bioscience's main competitors?
Direct peers on record are Protalix BioTherapeutics, Seres Therapeutics and Vedanta Biosciences. Emerging players are Novavax, Ginkgo Bioworks, Absci and InVitria. Broad incumbents are Amgen, Genentech (Roche) and BioMarin Pharmaceutical.
Does Lumen Bioscience have an API?
No public API is recorded for Lumen Bioscience.
What industry is Lumen Bioscience in?
Lumen Bioscience's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAKAF, Process Development & Tech Transfer Services (upstream/downstream), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2836.